Neurocritical Care

, Volume 8, Issue 3, pp 430–433 | Cite as

Baclofen and Gamma-Hydroxybutyrate Withdrawal

  • Jennifer L. LeTourneau
  • Daniel S. Hagg
  • Stephen M. Smith
Article

Abstract

Introduction

Benzodiazepine treatment of life-threatening gamma-hydroxybutyrate (GHB) withdrawal is frequently unsatisfactory. Animal studies suggest strongly that treatment with GABAB agonists, such as baclofen, will be a more effective strategy.

Methods

A case report from the medical intensive care unit (ICU) of the university tertiary care hospital.

Results

A 61-year-old woman was admitted to the medical ICU for severe withdrawal symptoms from chronic GHB use. This manifested as delirium, tremor, and seizures despite only small decreases in GHB dose and treatment with benzodiazepines. The addition of baclofen allowed the rapid sequential decreases in the GHB dose without seizure or delirium and resulted in long-term improvement of her tremor.

Conclusions

Baclofen, a GABAB agonist, may be a useful agent in the treatment of severe GHB withdrawal.

Keywords

Gamma-hydroxybutyrate dependence Baclofen Intention tremor 

List of Abbreviations

g

Grams

GABA

Gamma-aminobutyric acid

GHB

Gamma-hydroxybutyrate

h

Hours

ICU

Intensive care unit

mg

Milligrams

References

  1. 1.
    Teter CJ, Guthrie SK. A comprehensive review of MDMA, GHB: two common club drugs. Pharmacotherapy 2001;21(12):1486–513.PubMedCrossRefGoogle Scholar
  2. 2.
    Miro O, Nogue S, Espinosa G, To-Figueras J, Sanchez M. Trends in illicit drug emergencies: the emerging role of gamma-hydroxybutyrate. J Toxicol Clin Toxicol 2002;40(2):129–35.PubMedCrossRefGoogle Scholar
  3. 3.
    Snead OC III, Gibson KM. Gamma-hydroxybutyric acid. N Engl J Med 2005;352(26):2721–32.PubMedCrossRefGoogle Scholar
  4. 4.
    Fuller DE, Hornfeldt CS. From club drug to orphan drug: sodium oxybate (Xyrem) for the treatment of cataplexy. Pharmacotherapy 2003;23(9):1205–9.PubMedCrossRefGoogle Scholar
  5. 5.
    A double-blind, placebo-controlled study demonstrates sodium oxybate is effective for the treatment of excessive daytime sleepiness in narcolepsy. J Clin Sleep Med 2005;1(4):391–7.Google Scholar
  6. 6.
    Poldrugo F, Addolorato G. The role of gamma-hydroxybutyric acid in the treatment of alcoholism: from animal to clinical studies. Alcohol Alcohol 1999;34(1):15–24.PubMedGoogle Scholar
  7. 7.
    UCB and Jazz Pharmaceuticals Announce Expansion of Xyrem License to Include Fibromyalgia Syndrome (2006). http://www.jazzpharma.com/news.php?id=32.
  8. 8.
    Addolorato G, Castelli E, Stefanini GF, Casella G, Caputo F, Marsigli L, Bernardi M, Gasbarrini G. An open multicentric study evaluating 4-hydroxybutyric acid sodium salt in the medium-term treatment of 179 alcohol dependent subjects. GHB Study Group. Alcohol Alcohol 1996;31(4):341–5.PubMedGoogle Scholar
  9. 9.
    Freese TE, Miotto K, Reback CJ. The effects and consequences of selected club drugs. J Subst Abuse Treat 2002;23(2):151–6.PubMedCrossRefGoogle Scholar
  10. 10.
    Gallimberti L, Spella MR, Soncini CA, Gessa GL. Gamma-hydroxybutyric acid in the treatment of alcohol and heroin dependence. Alcohol 2000;20(3):257–62.PubMedCrossRefGoogle Scholar
  11. 11.
    Dyer JE, Roth B, Hyma BA. Gamma-hydroxybutyrate withdrawal syndrome. Ann Emerg Med 2001;37(2):147–53.PubMedCrossRefGoogle Scholar
  12. 12.
  13. 13.
    McDonough M, Kennedy N, Glasper A, Bearn J. Clinical features and management of gamma-hydroxybutyrate (GHB) withdrawal: a review. Drug Alcohol Depend 2004;75(1):3–9.PubMedCrossRefGoogle Scholar
  14. 14.
    Snead OC III, Liu CC. GABAA receptor function in the gamma-hydroxybutyrate model of generalized absence seizures. Neuropharmacology 1993;32(4):401–9.PubMedCrossRefGoogle Scholar
  15. 15.
    Goodwin AK, Griffiths RR, Brown PR, Froestl W, Jakobs C, Gibson KM, Weerts EM. Chronic intragastric administration of gamma-butyrolactone produces physical dependence in baboons. Psychopharmacology (Berl) 2006;189(1):71–82.CrossRefGoogle Scholar
  16. 16.
    Wu Y, Ali S, Ahmadian G, Liu CC, Wang YT, Gibson KM, Calver AR, Francis J, Pangalos MN, Carter Snead O III. Gamma-hydroxybutyric acid (GHB) and gamma-aminobutyric acidB receptor (GABABR) binding sites are distinctive from one another: molecular evidence. Neuropharmacology 2004;47(8):1146–56.PubMedCrossRefGoogle Scholar
  17. 17.
    Gervasi N, Monnier Z, Vincent P, Paupardin-Tritsch D, Hughes SW, Crunelli V, Leresche N. Pathway-specific action of gamma-hydroxybutyric acid in sensory thalamus and its relevance to absence seizures. J Neurosci 2003;23(36):11469–78.PubMedGoogle Scholar
  18. 18.
    Hechler V, Ratomponirina C, Maitre M. Gamma-hydroxybutyrate conversion into GABA induces displacement of GABAB binding that is blocked by valproate and ethosuximide. J Pharmacol Exp Ther 1997;281(2):753–60.PubMedGoogle Scholar
  19. 19.
    Bormann J, Hamill OP, Sakmann B. Mechanism of anion permeation through channels gated by glycine and gamma-aminobutyric acid in mouse cultured spinal neurones. J Physiol 1987;385:243–86.PubMedGoogle Scholar
  20. 20.
    Smith SM, Zorec R, McBurney RN. Conductance states activated by glycine and GABA in rat cultured spinal neurones. J Membr Biol 1989;108(1):45–52.PubMedCrossRefGoogle Scholar
  21. 21.
    Cruz HG, Ivanova T, Lunn ML, Stoffel M, Slesinger PA, Luscher C. Bi-directional effects of GABA(B) receptor agonists on the mesolimbic dopamine system. Nat Neurosci 2004;7(2):153–9.PubMedCrossRefGoogle Scholar
  22. 22.
    Kaupmann K, Cryan JF, Wellendorph P, Mombereau C, Sansig G, Klebs K, Schmutz M, Froestl W, van der Putten H, Mosbacher J, et al. Specific gamma-hydroxybutyrate-binding sites but loss of pharmacological effects of gamma-hydroxybutyrate in GABA(B)(1)-deficient mice. Eur J Neurosci 2003;18(10):2722–30.PubMedCrossRefGoogle Scholar
  23. 23.
    Smith MA, Gergans SR, Lyle MA. The motor-impairing effects of GABA(A) and GABA(B) agonists in gamma-hydroxybutyrate (GHB)-treated rats: cross-tolerance to baclofen but not flunitrazepam. Eur J Pharmacol 2006;552(1–3):83–9.PubMedCrossRefGoogle Scholar
  24. 24.
    Perez E, Chu J, Bania T. Seven days of gamma-hydroxybutyrate (GHB) use produces severe withdrawal. Ann Emerg Med 2006;48(2):219–20.PubMedCrossRefGoogle Scholar
  25. 25.
    Chew G, Fernando A III. Epileptic seizure in GHB withdrawal. Australas Psychiatry 2004;12(4):410–11.PubMedCrossRefGoogle Scholar
  26. 26.
    Quang LS, Desai MC, Kraner JC, Shannon MW, Woolf AD, Maher TJ. Enzyme and receptor antagonists for preventing toxicity from the gamma-hydroxybutyric acid precursor 1,4-butanediol in CD-1 mice. Ann NY Acad Sci 2002;965:461–72.PubMedCrossRefGoogle Scholar
  27. 27.
    Mullins ME, Fitzmaurice SC. Lack of efficacy of benzodiazepines in treating gamma-hydroxybutyrate withdrawal. J Emerg Med 2001;20(4):418–20.PubMedCrossRefGoogle Scholar
  28. 28.
    Turner MR, Gainsborough N. Neuroleptic malignant-like syndrome after abrupt withdrawal of baclofen. J Psychopharmacol 2001;15(1):61–3.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press Inc. 2008

Authors and Affiliations

  • Jennifer L. LeTourneau
    • 1
  • Daniel S. Hagg
    • 1
  • Stephen M. Smith
    • 1
  1. 1.Division of Pulmonary & Critical Care Medicine and Center for Intensive Care Research, Department of MedicineOregon Health & Science UniversityPortlandUSA

Personalised recommendations